Ithaca, NY – November 16, 2011 – Rheonix today announced the appointment of two individuals—Tom Karpen as Vice President of Operations overseeing engineering, production and quality teams and Terry Howell as Quality Manager. These two new members to the management team will be instrumental as the Company moves toward commercialization of its Rheonix CARD® system, a powerful automated microfluidic platform capable of analyzing raw clinical samples in a variety of diagnostic applications.
“Rheonix has a history of developing innovative solutions to complex problems in the molecular diagnostic field,” said Tony Eisenhut, Rheonix’s President. “With the addition of Tom and Terry to our team, we are focusing our efforts on the goal of bringing our flexible, scalable, integrated microfluidic platform to commercial reality in a number of growing markets.”
Mr. Karpen brings to Rheonix more than 20 years of experience in increasing value through innovative product development and bringing high growth and profit to businesses. Before joining Rheonix, Mr. Karpen managed R&D, quality and production engineering teams for GE Inspection Technologies in Skaneateles, NY. Prior to that, he was Director of Engineering at Everest-VIT, a company spun out of Welch Allyn. He grew the technology team from five to 60 individuals and eventually a successful sale to GE. Mr. Karpen has a BA in Physics from SUNY Geneseo and a BS in Electrical and Computer Engineering from Clarkson University.
Mr. Howell had more than a decade of experience in the biotechnology field, leading quality/regulatory efforts and bioassay development. He spent the majority of that time with Stryker Biotech in Hopkinton, MA managing bioassay quality control, and most recently at Percivia in Cambridge, MA, directing bioassay lab operations and developing quality systems. Mr. Howell has a BS in Animal Science from Virginia Tech and an MBA from Northeastern University.
Rheonix will display its CARD system, including a novel method for automatically extracting and amplifying nucleic acid from fresh tissue and formalin-fixed, paraffin-embedded (FFPE) samples, November 17 – 19, 2011, at Association for Molecular Pathology Annual Meeting in Grapevine Texas, booth #1003.